Cytosorbents (CTSO) Total Current Liabilities (2010 - 2026)

Cytosorbents' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $16.3 million for Q1 2026.

• Quarterly Total Current Liabilities rose 67.45% year-over-year to $16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 67.45% YoY) and the FY2025 annual result came in at $9.7 million, down 1.18% from the prior year.
• Total Current Liabilities was $16.3 million for Q1 2026 at Cytosorbents, up from $9.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $16.3 million in Q1 2026 and bottomed at $8.3 million in Q3 2024.
• A 5-year average of $11.0 million and a median of $10.0 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 35.57% — and 2026, when it soared 67.45%.
• Cytosorbents' Total Current Liabilities stood at $9.7 million in 2022, then soared by 44.48% to $14.0 million in 2023, then dropped by 30.0% to $9.8 million in 2024, then fell by 1.18% to $9.7 million in 2025, then surged by 67.92% to $16.3 million in 2026.
• Business Quant data shows CTSO's Total Current Liabilities at $16.3 million in Q1 2026, $9.7 million in Q4 2025, and $10.1 million in Q3 2025.